|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 28, 2017 ) Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood) .
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 9, 5, 11, 1 and 1 respectively.
Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/ventilator-associated-pneumonia-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease) .
- The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001884150/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Achaogen Inc
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Cardeas Pharma Corp
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Lakewood-Amedex Inc
MedImmune LLC
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001884150/discount
List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP) , H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor Ltd, H2 2017
Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001884150/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
